A B S T R A C T Vitamin A and its analogues (retinoids) affect normal and malignant hematopoietic cells. We examined the effect of retinoids on the clonal growth in vitro of myeloid leukemia cells. Retinoic acid inhibited the clonal growth of the KG-1, acute myeloblastic leukemia, and the HL-60, acute promyelocytic leukemia, human cell lines. The KG-1 cells were extremely sensitive to retinoic acid, with 50% of the colonies inhibited by 2.4-nM concentrations of the drug. A 50% growth inhibition of HL-60 was achieved by 25 nM retinoic acid. Complete inhibition of growth of both leukemia cell lines was seen with 1 gM retinoic acid. Exposure of KG-1 cells to retinoic acid for only 3-5 d was sufficient to inhibit all clonal growth. The all-trans and 13-cis forms of retinoic acid were equally effective in inhibiting proliferation. Retinal, retinyl acetate, and retinol (vitamin A) were less potent inhibitors. Clonal growth of the human K562 and mouse M-1 myeloid leukemic cell lines was not affected by 10 MM retinoic acid. Retinoic acid also inhibited the clonal growth of leukemia cells from five of seven patients with acute myeloid leukemia. Retinoic acid at concentrations of 5 nM to 0.3 gM inhibited 50% clonal growth, and 1 ,uM retinoic acid inhibited 64-98% of the leukemic colonies. The inhibition of clonal growth of KG-1 and HL-60 cell lines and of leukemic cells from two patients was not associated with the presence of a specific cytoplasmic retinoic acid-binding protein. Our study suggests that retinoic acid may prove to be effective in the treatment of human myeloid leukemia.
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Received for publication 26 August 1981 and in revised form 5 October 1981. tissue (1, 2) . Retinoids inhibit carcinogenesis in a variety of animal models (2, 3) , suppress in vitro malignant transformation of certain cell lines (4, 5) , and inhibit the growth of several tumor cell lines (6) (7) (8) (9) . Retinoids induce differentiation of mouse embryonal carcinoma cell lines (10) . The recent discovery of a specific cytoplasmic retinoic acid-binding protein (cRABP)' in various tissues has led to the hypothesis that retinoids may bind to cRABP, be transported to the nucleus, and modify gene expression (8) . Recent evidence suggests that retinoids are involved in growth and differentiation of hematopoietic cells. We have shown that retinoic acid at a concentration of 0.1 yM can enhance clonal growth of normal human myeloid stem cells (11) . Breitman et al. (12, 13) reported that low concentrations of retinoic acid induced the human promyelocytic leukemia cell line (HL-60) and cells from patients with acute promyelocytic leukemia to differentiate to morphologically and functionally mature granulocytes. This effect was limited to the promyelocytic type of myeloid leukemia, because retinoic acid did not induce differentiation of other subgroups of acute myeloid leukemia.
We studied the effect of retinoids on the clonal growth in soft gel culture of cells from three human acute myeloid leukemia (AML) cell lines, one mouse AML cell line, and leukemic cells freshly obtained from patients with myeloid leukemia. The colony formation assay provides a sensitive method for the study of the clonal proliferation of hematopoietic stem cells in the presence of chemically defined agents (14) . In the present study we found that clonal growth of a number of myeloid leukemic cells is inhibited by retinoids. Inhibition of growth was not mediated by a cytoplasmic retinoic acid-binding protein.
METHODS
Cells. Three human AML cell lines, KG-1, HL-60, and K562 have been established (15) . The KG-1 cell line was derived from a patient with erythroleukemia. The KG-1 cells are at the myeloblast stage of differentiation and retain the morphological and cytochemical characteristics of AML cells (16) . The HL-60 cell line was derived from a patient with promyelocytic leukemia and the cells are predominantly at the promyelocytic stage of differentiation (17) . The K562 cells were established from the pleural fluid of a patient with chronic myeloid leukemia in blastic crisis (18) and are composed of undifferentiated blast cells. The M-1 is a mouse AML cell line established from a spontaneous murine myeloid leukemia (19) . All cells were maintained in continuous suspension culture in T flasks (Lux Scientific Corp., Newbury Park, Calif.) with alpha modified minimum essential medium (Flow Laboratories, Inc., Rockville, Md.), 20% fetal calf serum (Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y.), penicillin, and streptomycin. The cells were grown in a humidified incubator with 5% CO2 at 370C and were refed twice weekly. Experiments were performed on cells that were in their logarithmic growth phase (2-3 d after subculturing in fresh medium).
Leukemic cells were obtained from the peripheral blood or bone marrow of four patients with AML, one patient with acute myelomonocytic leukemia and two patients with chronic myelocytic leukemia in myeloid blast crisis. We also classified their leukemic type according to the FrenchAmerican-British classification for leukemia (20) The KG-1 cell line requires colony-stimulating factor (CSF) for its growth. The CSF was conditioned medium from a human T-lymphocyte cell line known as Mo (21) . It was added to the cultures at an optimal growth-stimulating concentration (1.5%). The HL-60, K562, and M-1 cells form colonies without CSF. The same lot of CSF-and Mo-conditioned medium was used for all experiments. The cloning efficiency of each cell type varies, and to have a convenient number of colonies in each plate, the KG-1 cells were plated at 4 X 101, HL-60 at 1.5 X 103, K562 at 1 X 103, and M-1 at 4 X 103 cells/dish. The cloning efficiency of the KG-1 cell in the presence of CSF was 4%. The cloning efficiency of HL-60, K562, and M-1 was 32, 79, and 18%, respectively. These cells were plated without CSF.
Leukemic cells freshly obtained from patients were grown by the two-layer agar technique. The CSF was provided by underlayers prepared with 1 X 106 normal human peripheral blood leukocytes in alpha medium, fetal calf serum, and 0.5% agar together with 0.1 ml retinoic acid solution. We have found that fresh leukemic cells form colonies more readily with leukocyte underlayers than with Mo-conditioned medium. A total of 2 X 105 leukemic cells/ml were seeded as overlayers by a method similar to that used for the cell lines. The culture dishes were incubated at 370C in a humidified atmosphere containing 5% CO2 for 10-14 d. Colonies (240 cells) and clusters (10-40 cells) were scored with the aid of an inverted microscope. In each experiment three to four dishes per point were seeded.
Assay for cytoplasmic retinoic acid-binding protein. The KG-1 and HL-60 cells were grown in suspension cultures as described above and washed three times with PBS. We also studied the cells from the 3T6 mouse fibroblast line as a positive control because they have cRABP (8) . These cells were grown in a monolayer culture in Dulbecco's modification of Eagle's medium and 10% fetal calf serum. They were collected with 0.25% trypsin and washed three times with PBS. Each of the cell types (3 X 108 -5 X 108 cells) was pelleted and homogenized by sonication for 30 s in 50 nM of Tris-HCI buffer, pH 7.5. The homogenate was centrifuged for 10 min at 31,000 g, and the suspension was spun again for 1 h at 105,000 g. The protein concentration in the cytosol was between 11 and 17 mg/ml. The supernatant cytosol was tested for the presence of cRABP according to the method of Ong and Chytil (22) . In brief, the cytosol was incubated with 50 nM [3H]retinoic acid (40 Ci/mmol, Hoffmann-La Roche, Inc.) for 5 h at 4°C in subdued light. Separate cytosol samples were incubated with 50 nM [3H]retinoic acid plus 200 M excess unlabeled retinoic acid to measure nonspecific binding. The cytosol samples were mixed for 5 min with a 1% charcoal-dextran suspension to absorb the unbound retinoic acid. The charcoal-coated dextran was removed by centrifugation, and 0.2 ml of the cytosol supernatant was applied on the top of a 5-20% sucrose gradient containing 10 mM Tris-HCI, pH 7.5, 1 mM disodium EDTA, 10 mM KCl, and 10 mM monothioglycerol. The sucrose gradients were spun at 220,000 g for 20 h at 4°C. Fractions of 0.250 ml were collected and counted for tritium with a liquid scintillation spectrophotometer (model LS-330, Beckman Instruments, Inc., Fullerton, Calif.). We determined how long KG-1 cells must be exposed to retinoic acid for clonal proliferation to be inhibited. The KG-1 cells (1.5 X 105) were suspended in liquid culture containing 1 ,IM retinoic acid, alpha medium, 15% fetal calf serum, and 10 ,l/ml Mo-conditioned medium. Control cells were grown in liquid culture without retinoic acid. The cells were harvested and counted after 1, 8, and 24 h and then at daily intervals. Cell growth in liquid culture was slower in the presence of retinoic acid as compared with controls (data not shown). However, no difference in viability was noted between cells from the retinoic acid-containing cultures and control cultures as judged by trypan blue viability (85% or more viable cells after 5 d in liquid culture). The cells were washed three times in alpha medium, counted, and plated at 4 X 108 cells/dish in agar with Mo-conditioned medium but without retinoic acid. After 48 h in liquid culture with retinoic acid the KG-1 cells had a reduced clonal growth as compared with cells from control cultures (Fig. 2) (Fig. 3) . We found that 13-cis-retinoic acid was as effective as all-trans-retinoic acid in inhibiting the growth of the KG-1 cells. Fig. 4 ). In these five patients, 1 MM retinoic acid inhibited the growth of 64-98% of the colonies and clusters (Fig. 4) . Retinoic acid at a concentration of 10 MM inhibited only 45% of leukemic cell clonal growth from patient 6 and did not affect the proliferation of cells from patient 7 (Fig. 4) (Fig. 5B-E) .
A mixing experiment was performed to ensure that leukemic lysosomal enzymes were not degrading the cRABP when the cytosol was prepared. The cytosol from the KG-I and HL-60 cells were each mixed with the 3T6 cell cytosol in equal proportions and the mixture was examined for cRABP. The cytosol of the KG-1 and of the HL-60 cells did not affect the cRABP of the 3T6 cells (Fig. 5F) .
DISCUSSION
The data presented shows that retinoic acid inhibited the clonal growth of two human myeloid leukemia cell lines, KG-1 and HL-60. The KG-1 cell line was extremely sensitive to retinoic acid, and 50% of the col- In contrast, we found in the patients studied that clonal growth of AML (Ml and M2) and acute myelomonocytic leukemia (M4) cells were inhibited by retinoic acid. Retinoic acid did not induce morphological, histochemical, or functional differentiation of the cells from the KG-I cell line or from the patients (data not shown). In the patient studies, the inhibited colonies probably were not derived from normal hematopoietic stem cells. Studies with chromosomal markers have shown that the colonies developing in the soft gel colony assay from cells of leukemic patients are derived from the leukemic clone (23) . Also, we (11) have shown that 10 nM-l AM retinoic acid enhances normal human myeloid clonal proliferation. We found that the clonal growth of the human blast cell line K562, the murine M-1 cells, and leukemic cells from two of seven patients was not inhibited by retinoic acid. The reason for the heterogeneity of response to retinoic acid is not clear at this time.
The acid forms of vitamin A, i.e., retinoic acid and its i3-cis analogue, were the most potent retinoids in inhibiting the growth of the KG-1 cells. Other investigators have found that the acid forms of vitamin A have the greatest antitumor effect in several biological systems (6) . The alcohol and aldehyde forms of vitamin A (retinol and retinal, respectively) can be metabolically oxidized to retinoic acid. Retinoic acid or one of its metabolites may be the active substance in a variety of biological systems. Lacroix and Lippman (9) have reported that the growth inhibition of retinoic acid on cells from human breast cancer cell lines is reversible after the removal of retinoic acid. We found that the inhibitory effect of retinoic acid on clonal growth of KG-1 cells was not reversible after its removal from the cells. The irreversibility may have been due to a cytotoxic effect. The mechanism of inhibition of leukemic growth by retinoic acid is not clear, but our data does suggest that the inhibition is probably more than a nonspecific toxic effect. Inhibition of KG-1, HL-60, and 70% of leukemic patient cells occurred at very low concentrations of retinoic acid. Furthermore, cellular viability in liquid culture of KG-1 and HL-60 cells was not reduced by prolonged exposure to 1 MM retinoic acid. Likewise, the growth of the K562 and M-1 cells was not affected by 10 MM of retinoic acid. We previously have shown that retinoic acid and other retinoids enhanced the CSF-stimulated clonal growth of normal myeloid progenitor cells (11) The mechanism of action of retinoids in various biological systems is unknown. A specific cRABP receptor has been identified in several normal and neoplastic tissues (8, 9, 22, 24) , and it has been proposed that the biological effects of retinoic acid might be mediated by this receptor (8) . Investigators (25, 26) have found that the ability of retinoids to bind to cRABP correlates with its biological activity in a variety of biological systems. Frequently, however, the sensitivity of the cells to growth inhibition by retinoic acid did not correlate with the level of cRABP in the cell (27) . We demonstrate here that the clonal growth of two human myeloid leukemic cell lines and cells from two patients with AML was inhibited by low concentrations of retinoic acid, but the cells did not have detectable cRABP. Our studies add further support to the view presented by Lotan et al. (27) The data reported here suggest that retinoic acid could play a role in treatment of human myeloid leukemia. 13-cis-retinoic acid is given systemically to patients with dermatologic diseases with few side effects (30) (31) (32) . Retinoic acid serum levels of 0.3-0. 5 ,ug/ml (-1 AM) are attainable (33) . Also, the ability of retinoic acid to enhance normal granulopoiesis may be of additional benefit. In addition, the KG-1 cell line may provide a useful model for the study of the mechanism of inhibitory action of retinoids on human leukemic cells and provide a convenient assay system for examining the inhibitory effect of newly synthesized retinoids. 
